# US 2022/0054563 A1 · Dosing regime and formulations for type b adenoviruses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0054563 A1
- Document ID: US20220054563A1
- Status: Published application
- Kind: A1
- Application number: 17/448,549
- Filed: 2021-09-23
- Published: 2022-02-24
- Earliest claimed: 2013-06-14
- Assignees: Psioxus Therapeutics Limited
- Applicants: Psioxus Therapeutics Limited
- Inventors: John Beadle; Kerry Fisher; Christine Wilkinson Blanc
- Web page: https://patentgrep.com/patent/US20220054563A1

## CPC

- A61K 35/761: Adenovirus
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 33/243: Platinum; Compounds thereof
- A61K 38/19: Cytokines; Lymphokines; Interferons
- A61K 38/2013: {IL-2}
- A61K 38/212: {IFN-alpha}
- A61K 38/217: {IFN-gamma}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 2710/10021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2710/10032: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2710/10071: Demonstrated in vivo effect
- C12N 2710/10332: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present disclosure provides a method of treating a human patient comprising the steps of: systemically administering multiple doses of a parenteral formulation of a replication capable oncolytic adenovirus of subgroup B in a single treatment cycle, wherein the total dose given in each dose is in the range of 1×1010 to 1×1014 viral particles, and wherein each dose of virus is administered over a period of 1 to 90 minutes, for example at a rate of viral particle delivery in the range of 2×1010 particles per minute to 2×1012 particles per minute. The disclosure further extends to formulations of the said oncolytic adenoviruses and combination therapies of the viruses and formulations with other therapeutic agents.

## Claims

### Claim at position 1

-27. (canceled)

### Claim 28

A method of treating cancer in a human patient, comprising intravenously administering to the patient multiple doses of a formulation of a replication competent oncolytic adenovirus of subgroup B in a single treatment cycle,
wherein a total dose given in each administration is in the range of 1×1012 to 1×1013 viral particles, and
wherein the rate of viral particle delivery for each administered dose of adenoviruses is in the range of 2×1010 to 6×1011 particles per minute.

### Claim 29 (depends on 28)

The method of claim 28, wherein the period between each dose administration is in the range of 6 hours to 72 hours.

### Claim 30 (depends on 28)

The method of claim 28, wherein the multiple doses are 2, 3, 4, 5, 6 or 7 doses in a single treatment cycle.

### Claim 31 (depends on 28)

The method of claim 28, wherein the treatment cycle is a period of 14 days or less.

### Claim 32 (depends on 28)

The method of claim 28, wherein each dose of adenovirus is administered such that the rate of viral particle delivery is in the range of 1×1011 to 3×1011 viral particles per minute.

### Claim 33 (depends on 28)

The method of claim 28, wherein 1×1013 viral particles are administered over a 60 minute period per dose or wherein 6×1012 viral particles are administered over a 40 minute period per dose.

### Claim 34 (depends on 28)

The method of claim 28, wherein a blood level of the adenovirus after administration of a second and optionally subsequent doses reaches a blood level of at least 2×106 viral particles per mL.

### Claim 35 (depends on 34)

The method of claim 34, wherein the blood level of viral particles is maintained for 15 minutes or greater.

### Claim 36 (depends on 28)

The method of claim 28, wherein the volume of the formulation administered is 100 mL or less.

### Claim 37 (depends on 28)

The method of claim 28, wherein the multiple doses comprise a first dose that is administered on day 1, a second dose that is administered on day 3, and a third dose that is administered on day 5, and further wherein no dose is administered on day 2 or on day 4.

### Claim 38 (depends on 28)

The method of claim 28, wherein the adenovirus is a chimeric adenovirus.

### Claim 39 (depends on 38)

The method of claim 38, wherein the adenovirus is unconjugated.

### Claim 40 (depends on 28)

The method of claim 28, wherein the adenovirus is Enadenotucirev (EnAd).

### Claim 41 (depends on 28)

The method of claim 28, wherein the adenovirus is administered in combination with the administration of an anti-cancer therapy, wherein the anti-cancer therapy is an immunotherapeutic agent, a small molecule inhibitor, radiotherapy, radio-isotope therapy or any combination thereof.

### Claim 42 (depends on 28)

The method of claim 28, wherein the adenovirus is administered in combination with the administration of one or more prophylactic agents.

### Claim 43 (depends on 28)

The method of claim 28, for the treatment of a tumour.

### Claim 44 (depends on 28)

The method of claim 28, wherein the first dose in the treatment of a given cycle is a lower dose than the dose administered in subsequent treatments in the cycle.

### Claim 45 (depends on 28)

The method of claim 28, wherein the same total dose is given in the first and the second administrations.

### Claim 46 (depends on 28)

The method of claim 28, wherein the same total dose is given for all of the administered doses in the cycle.

### Claim 47 (depends on 28)

The method of claim 28, wherein the administration of the multiple doses of replication competent oncolytic adenovirus seeds viral infection in the cancer cells.
